Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South Africa
At a press conference at ESMO 2014, Dr Rapoport presents the results of his phase 3 trial which looked at the use of rolapitant for the prevention of chemotherapy-induced nausea and vomiting.